# Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

> **NCT02217475** · PHASE2 · COMPLETED · sponsor: **Tobira Therapeutics, Inc.** · enrollment: 289 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Cenicriviroc
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02217475
- **Lead sponsor:** Tobira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-18
- **Primary completion:** 2016-06-30
- **Final completion:** 2017-06-22
- **Target enrollment:** 289 (ACTUAL)
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02217475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02217475, "Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02217475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*